Methotrexate as a Corticosteroid-Sparing Agent for Thyroid Eye Disease

Journal of Clinical & Experimental Ophthalmology
Erick Rivera-GranaJames T Rosenbaum

Abstract

Thyroid eye disease (TED) is generally treated with oral corticosteroid therapy. A steroid sparing drug could be a useful adjunct. We reviewed our experience with methotrexate as a corticosteroid sparing agent to treat TED. Retrospective chart review from two eye inflammation clinics. Patients with TED who were unable to discontinue prednisone therapy without disease recurrence were included. 14 patients who were receiving an average of 32 mg/day of prednisone were treated with methotrexate, usually 15 mg/week orally or 20 mg/week subcutaneously. Five patients discontinued therapy for a lack of benefit or intolerance. Of the 9 patients who remained on methotrexate, all were able to discontinue prednisone completely after an average duration of 7.5 months. Improved visual acuity by at least two lines on the Snellen chart was achieved by 7 of 12 patients with reduced acuity and partial improvement in ocular motility was achieved in 5 of 14 patients. Methotrexate provided an effective steroid sparing effect in a subset of patients with TED.

Citations

Mar 12, 2016·Expert Review of Clinical Pharmacology·Marek Ruchała, Nadia Sawicka-Gutaj

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anti-inflammatory Treatments

A drug or substance that reduces inflammation (redness, swelling, and pain) in the body. Anti-inflammatory agents block certain substances in the body that cause inflammation and swelling. Discover the latest research on anti-inflammatory treatments here

Related Papers

American Journal of Ophthalmology
J E LEBENSOHN
Journal of Ophthalmic & Vision Research
Mohsen Bahmani-KashkouliSara Jam
© 2021 Meta ULC. All rights reserved